Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 113Leukemia 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Lymphoma, Non-Hodgkin 59Multiple Myeloma 56Leukemia, Myeloid, Acute 56Lymphoma, Large B-Cell, Diffuse 55Hodgkin Disease 48Myelodysplastic Syndromes 43Burkitt Lymphoma 43Lymphoma, Follicular 41Leukemia, Lymphocytic, Chronic, B-Cell 41Lymphoma, Mantle-Cell 40Breast Neoplasms 35Lymphoma, Large-Cell, Immunoblastic 34Sarcoma 27Neoplasms, Plasma Cell 27Central Nervous System Neoplasms 25Lymphoma, B-Cell, Marginal Zone 24Dendritic Cell Sarcoma, Interdigitating 19Recurrence 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 16Neuroblastoma 16Myeloproliferative Disorders 16Leukemia, Myeloid, Chronic-Phase 16Leukemia, Myeloid, Accelerated Phase 15Congenital Abnormalities 15Neutropenia 13Lung Neoplasms 13

Interventions

fludarabine phosphate 3midostaurin 2Whole-Body Irradiation 2Therapeutics 2Mycophenolic Acid 2Methotrexate 2Cyclosporine 2Busulfan 2thymoglobulin 1ibrutinib 1hydrocortisone valerate 1fludarabine 1denileukin diftitox 1avapritinib 1Thiotepa 1Tacrolimus 1Sunitinib 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Methylprednisolone 1Leucovorin 1Imatinib Mesylate 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Granisetron 1Filgrastim 1Epoetin Alfa 1Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Mast-Cell × Filgrastim × Clear all
NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stanford University

Phase 2 Completed
36 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡